(NYSEMKT: CYBN) Cybin's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.62%.
Cybin's earnings in 2025 is -$71,040,000.On average, 5 Wall Street analysts forecast CYBN's earnings for 2026 to be -$103,430,257, with the lowest CYBN earnings forecast at -$112,293,404, and the highest CYBN earnings forecast at -$92,627,720. On average, 5 Wall Street analysts forecast CYBN's earnings for 2027 to be -$64,764,546, with the lowest CYBN earnings forecast at -$72,533,620, and the highest CYBN earnings forecast at -$55,625,002.
In 2028, CYBN is forecast to generate -$77,704,557 in earnings, with the lowest earnings forecast at -$100,221,742 and the highest earnings forecast at -$52,600,752.